Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31724481 | 0.87 | CTSS (0.48) | CTSKCTSSPPARAITGB3ITGA2B | |
| SCHEMBL8667675 | 0.82 | CTSS (0.46) | CYP4A11CTSKCTSSPPARACYP4F2 | |
| SCHEMBL8667664 | 0.82 | CTSS (0.49) | CTSKCTSSPPARAITGB3ITGA2B | |
| SCHEMBL12801872 | 0.81 | CTSK (0.41) | CTSKCTSSITGB3ITGA2BCA2 | |
| SCHEMBL3379645 | 0.81 | CTSS (0.48) | CTSKCTSSNR1H2ITGB3ITGA2B | |
| SCHEMBL3379647 | 0.81 | CTSS (0.48) | CTSKCTSSNR1H2ITGB3ITGA2B | |
| SCHEMBL9973448 | 0.80 | CTSK (0.47) | CTSKCTSSPPARANR1H2PPARG | |
| SCHEMBL8666252 | 0.80 | MAPT (0.45) | CTSKCTSSPPARAITGB3ITGA2B | |
| SCHEMBL2582580 | 0.80 | CTSS (0.48) | CTSKCTSSKLK5 | |
| SCHEMBL14254331 | 0.80 | CTSS (0.48) | CTSKCTSSPPARAKLK5TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330065-A1 | RelA Inhibitors for Biofilm Disruption | DREXEL UNIVERSITY (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330065-A1 | RelA Inhibitors for Biofilm Disruption | DREXEL UNIVERSITY (US) | 2023-10-19 | — | — | US | disclosed |
| US-11666555-B2 | RelA inhibitors for biofilm disruption | DREXEL UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666555-B2 | RelA inhibitors for biofilm disruption | DREXEL UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-20200069647-A1 | RelA Inhibitors for Biofilm Disruption | DREXEL UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666555-B2 | RelA inhibitors for biofilm disruption | RELA, NFKBIA, NFKB1 | CYP4A11 3722/4885CTSK 1207/4885CTSS 1269/4885 |
| US-20230330065-A1 | RelA Inhibitors for Biofilm Disruption | RELA, NFKBIA, NFKB1 | CYP4A11 3722/4885CTSK 1207/4885CTSS 1269/4885 |
| US-20200069647-A1 | RelA Inhibitors for Biofilm Disruption | RELA, NFKBIA, NFKB1 | CYP4A11 3722/4885CTSK 1207/4885CTSS 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.